This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
IV Antibiotics, Antiemetic Recalled Because of Potential Contamination
By News Staff
The FDA said health care professionals should not use, and should remove from their pharmacy inventories, IV bag products manufactured by Claris and sold under the following labels:
- Claris (metronidazole, ciprofloxacin, ondansetron);
- Pfizer Inc. (metronidazole, ciprofloxacin, ondansetron);
- Sagent Pharmaceuticals Inc. (metronidazole, ondansetron); and
- West-Ward Pharmaceutical Corp. (metronidazole, ondansetron).
The agency said microbiological analysis of white matter in a bag of metronidazole identified the substance as a Cladosporium mold, which can cause infections in susceptible patients, including immunocompromised individuals.
Sagent said in a June 2 news release that such infections can be fatal. However, the FDA said it is not aware of any reports of injuries linked to administration of the recalled products.
White matter in a bag of ondansetron -- which is used to treat nausea and vomiting associated with chemotherapy or surgery -- also is being analyzed, said agency officials.
Patients who have received the recalled products should be observed for signs or symptoms of illness and treated appropriately.
Claris said questions about returning unused product should be directed to the company at (877) 725- 2747. Health care workers with medical questions about the products may call the same number and ask for medical affairs, the company said.
Adverse events associated with the use of recalled products should be reported to the FDA's MedWatch program.
FDA Public Health Alert: "Healthcare Professionals Warned Not To Use Certain Intravenous Metronidazole, Ondansetron and Ciprofloxacin Due To Potential Contamination"
(June 1, 2010)
Claris Lifesciences press release on nationwide voluntary recall
(June 1, 2010)
Claris: Urgent: Drug Product Recall Notification
(2-page PDF; About PDFs)
(May 30, 2010)
Claris: Customer Recall Return Response Form
(2-page PDF; About PDFs)
Sagent Pharmaceuticals news release on nationwide voluntary recall
(June 2, 2010)
This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
Remain Vigiliant for Novel Coronavirus, Says CDC
DTaP Remains in Short Supply This Summer
Though Waning, H7N9 Still Poses Pandemic Potential
AUA Says No to Routine PSA Screening
AAFP Criticizes Appeal of Plan B One-Step Ruling
AAFP to Hospitals: Stop Early Elective Deliveries
AAFP, USPSTF Differ Somewhat on HIV Screening Guidance
Zoledronic Acid Confers Both Pros, Cons
ACP Issues Guidance on PSA Screening
Abbott Recalls FreeStyle InsuLinx Blood Glucose Meter
Discuss Drug Options With Women at Risk for Breast Cancer
Shingles Vaccine Effective, But Uptake Is Low
Evidence Lacking to Make Oral Cancer Screening Recommendation
Two External Guidelines Get Qualified AAFP Endorsement
USPSTF Recommends BRCA Testing for High-risk Women
Primary Care, Public Health Look for Ways to Integrate
Malfunction Prompts Glucose Meter Recall
Evidence Lacking on PAD Screening, Says USPSTF
Azithromycin Poses Arrhythmia Risk, Says FDA
Vets With PTSD Often Prescribed Inappropriate Meds
AIM-HI Offers Grants to Combat Childhood Obesity
USPSTF Says No to Low-dose Vitamin D, Calcium to Prevent Fractures
PCV13, HibMenCY Vaccine Changes Approved by ACIP
AAFP, Other Groups Release More Choosing Wisely Lists
National Office Champions Tobacco Cessation Project Successful
USPSTF Issues Draft Statement on Glaucoma Screening
Study Examines Overuse, Inappropriate Use of Health Services
Apply to Become an AAFP Vaccine Science Fellow
Study Looks to Reduce PSA Screening Risks
AAP Issues New Clinical Guidance on Type 2 Diabetes
CDC: Adult Vaccination Rates Still Too Low
Pertussis Outbreaks Declining, but Immunization Still Key
2013 Immunization Schedules Include Several Changes
FDA Warns of Liver Injury Risk With Samsca Use
FDA Approves First Recombinant Trivalent Influenza Vaccine
AAFP, USPSTF: Screen Women of Childbearing Age for Partner Violence
Breast Cancer Screening in Older Women Costly, Likely Ineffective
CDC Gives Flu Update, Urges Continued Vaccination
Aerobic Exercise Beats Resistance Training for Weight Control
